Viome’s Oral and Throat Cancer Detection Test Built on Viome’s Metatranscriptomics and AI Platform Receives FDA Breakthrough Device Designation
The human body talks. It speaks through biochemicals, and if you know how to listen - it can tell you remarkable things. Just as it can make you feel happy or sad, it can also communicate when things are going awry.
Inside each of us are complex mechanisms that signal to cells and to systems that something is wrong. These signals are often packaged in small molecules that interact with different types of cells - from our blood cells to our brain cells, our gut cells, and beyond. Scientists refer to patterns of molecules as ‘biological markers’ - or biomarkers - a broad name for any biological activity connected to a specific health outcome or disease. Now Viome has created a new early detection tool that has received FDA Breakthrough Device designation to detect the biomarkers associated with Oral and Throat Cancer.
About The Food and Drug Administration’s Breakthrough Device Program
The FDA considers a technology worthy of breakthrough designation when it represents unparalleled innovation with no cleared alternatives, has the potential to be a more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions, and has the opportunity to benefit the lives of many patients.
A Breakthrough in Diagnostics
When Viome set out to map the gut microbiome and examine the unique patterns and trends of microbes in our gut, we saw the potential for so much more. Our goals included analyzing them and comparing this data against many health conditions. And in our various studies, we have utilized the information from key biomarkers to determine how effective our recommendations were at improving health.
This has led us to one of our greatest endeavors: using our proprietary technology and AI platform to aid in screening for other conditions like cancer. Focusing first on Oral and Throat Cancer, two life-threatening diseases typically diagnosed by a physical examination from primary care clinicians, we sought to reduce the number of cases that go undetected for too long. The truth is all too common: many individuals find out they may have cancer long after it has manifested. But now, with a simple saliva test, Viome can analyze samples for the presence of Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal Squamous Cell Carcinoma (OPSCC).1
Our ability to examine mRNA sequences (determining the level of expression from specific genes) and compare them against a database of biomarkers (not to mention utilizing our incredible machine learning techniques) makes determining your risk of disease faster than ever. Faster answers can mean better outcomes and get you the information you need to seek clinical help more rapidly.
And this is just one example of how Viome is working to prevent and reverse chronic diseases. So far, we’ve developed more than 30 precision biomarkers for the early detection of cancers, metabolic diseases, autoimmune diseases, neurodegenerative diseases, and mental health conditions.
It’s this same technology and expertise we’ve used to generate our new Oral and Throat Cancer detection test, so you can imagine there is still a ton of information that gets captured and sent back into the algorithm with every test. Just like us, our algorithm is constantly evolving and learning and making smarter and smarter decisions.
Up and Onward with Disease Research
In line with our mission to eradicate chronic diseases, we remain optimistic by the untapped potential of the gut microbiome. We have seen how connected the microbes that call us home are too many regions of the body. And how connected they are to each other!
Together, we will continue to create innovative new methods for diagnosis and treatment of the many conditions that plague the world. And by using the impressive power behind our dietary choices, we can continue to break down the barriers of disease and treat our food with respect as the most potent form of preventative medicine.
1. Banavar G, Ogundijo O, Julian C, et al. Detecting salivary host-microbiome RNA signature for aiding diagnosis of oral and throat cancer. July 2022. https://doi.org/10.1101/2022.07.30.22278239